Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer

NCT01329627 is registered in ClinicalTrials.gov with Instituto do Cancer do Estado de São Paulo as lead sponsor.

NCT NCT01329627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01329627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Feasibility Study of Weekly Paclitaxel Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide for Locally Advanced HER2-Negative Breast Cancer
Lead sponsor
Instituto do Cancer do Estado de São Paulo
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2010
Completion date
August 31, 2012
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced her2-negative breast cancer